Condition: Metastatic Hormone-sensitive Prostate Cancer · Sponsor: Novartis Pharmaceuticals
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from participants randomized in the study will be evaluated
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| University of California San Diego - Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Saint Johns Cancer Institute | Santa Monica, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Denver, Colorado, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Advanced Urology Ins Daytona Beach | Daytona Beach, Florida, United States | Recruiting |
| Emory University School of Medicine-Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Associated Urological Specialists | Chicago Ridge, Illinois, United States | Recruiting |
| American Oncology Partners PA Center for Cancer and Blood Disorders | Bethesda, Maryland, United States | Recruiting |
| Mass General Hospital | Boston, Massachusetts, United States | Recruiting |
| Michigan Institute of Urology | West Bloomfield, Michigan, United States | Recruiting |
| XCancer Omaha LLC | Omaha, Nebraska, United States | Recruiting |
| Perlmutter Cancer Centre | New York, New York, United States | Recruiting |
+ 55 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06991556